In an aggressive mouse AML model, we demonstrated that rIL-33 treatment enhanced tumor protective effects by strongly increased expansion of leukemia-reactive CD8+ IFN-γ+ T cells, which resulted in delayed leukemia development and increased overall survival. Here, CD8A is linked to leukemia.